Ensysce Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters11-16

* Ensysce Biosciences Inc reported quarterly adjusted earnings of 7 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -87 cents. The mean expectation of two analysts for the quarter was for a loss of 29 cents per share. Wall Street expected results to range from -42 cents to -17 cents per share.

* Revenue rose 685.3% to $3.42 million from a year ago; analysts expected $250.00 thousand.

* Ensysce Biosciences Inc's reported EPS for the quarter was 7 cents.

* The company reported quarterly net income of $662 thousand.

* Ensysce Biosciences Inc shares had risen by 164.9% this quarter and lost 40.0% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 7.8% in the last three months.

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

*

* Wall Street's median 12-month price target for Ensysce Biosciences Inc is $8.30

This summary was machine generated from LSEG data November 15 at 10:00 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.29 0.07 Beat

Jun. 30 2024 -0.39 -0.22 Beat

Mar. 31 2024 -0.90 -0.55 Beat

Dec. 31 2023 -0.87 -1.37 Missed

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483536488?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-16 06:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483536488","market":"us","top_or_hot":-1,"title":"Ensysce Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary","media":"Reuters","content":"<html><body><p>* Ensysce Biosciences Inc    reported quarterly adjusted earnings of 7 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -87 cents.  The mean expectation of two analysts for the quarter was for a loss of 29 cents per share. Wall Street expected results to range from -42 cents to -17 cents per share.</p><p>   * Revenue rose 685.3% to $3.42 million from a year ago; analysts expected $250.00 thousand. </p><p>   * Ensysce Biosciences Inc's reported EPS for the quarter was 7 cents.</p><p>   * The company reported quarterly net income of $662 thousand.</p><p>   * Ensysce Biosciences Inc shares had risen by 164.9% this quarter and lost 40.0% so far this year.</p><p>FORECAST CHANGES</p><p>   * The mean earnings estimate of analysts had risen by about 7.8% in the last three months. </p><p>   * In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.</p><p>RECOMMENDATIONS</p><p>   * </p><p>   * Wall Street's median 12-month price target for Ensysce Biosciences Inc is $8.30 </p><p>This summary was machine generated from LSEG data November 15 at 10:00 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,</p><p>                                                MISSED</p><p>Sep. 30 2024      -0.29          0.07           Beat</p><p>Jun. 30 2024      -0.39          -0.22          Beat</p><p>Mar. 31 2024      -0.90          -0.55          Beat</p><p>Dec. 31 2023      -0.87          -1.37          Missed</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ensysce Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEnsysce Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-16 06:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>* Ensysce Biosciences Inc    reported quarterly adjusted earnings of 7 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ENSC","symbol_name":"Ensysce Biosciences Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2483536488","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483536488","pubTimestamp":1731708046,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"* Ensysce Biosciences Inc    reported quarterly adjusted earnings of 7 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -87 ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ENSC":"Ensysce Biosciences Inc."},"translate_title":"Ensysce Biosciences Inc报告截至9月30日的季度业绩-收益摘要","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENSC":0.9},"content_text":"* Ensysce Biosciences Inc    reported quarterly adjusted earnings of 7 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -87 cents.  The mean expectation of two analysts for the quarter was for a loss of 29 cents per share. Wall Street expected results to range from -42 cents to -17 cents per share.   * Revenue rose 685.3% to $3.42 million from a year ago; analysts expected $250.00 thousand.    * Ensysce Biosciences Inc's reported EPS for the quarter was 7 cents.   * The company reported quarterly net income of $662 thousand.   * Ensysce Biosciences Inc shares had risen by 164.9% this quarter and lost 40.0% so far this year.FORECAST CHANGES   * The mean earnings estimate of analysts had risen by about 7.8% in the last three months.    * In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.RECOMMENDATIONS   *    * Wall Street's median 12-month price target for Ensysce Biosciences Inc is $8.30 This summary was machine generated from LSEG data November 15 at 10:00 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,                                                MISSEDSep. 30 2024      -0.29          0.07           BeatJun. 30 2024      -0.39          -0.22          BeatMar. 31 2024      -0.90          -0.55          BeatDec. 31 2023      -0.87          -1.37          Missed","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483536488"}